Anthracycline and taxane containing chemotherapy for early-stage operable breast cancer: meta-analyses of 100,000 women in 86 randomised trials
Journal article
Taylor CAROLYN. et al, (2023), The Lancet
Early mortality risk with non-intensive acute myeloid leukemia (AML) therapies: analysis of 1336 patients from MRC/NCRI and SWOG.
Journal article
Othus M. et al, (2022), Leuk Lymphoma, 1 - 3
Longitudinal expression profiling identifies a poor risk subset of patients with ABC-type Diffuse Large B Cell Lymphoma.
Journal article
Bewicke-Copley F. et al, (2022), Blood Adv
A randomised comparison of FLAG-Ida versus daunorubicin combined with clofarabine in relapsed or refractory acute myeloid leukaemia: Results from the UK NCRI AML17 trial.
Journal article
Russell NH. et al, (2022), Br J Haematol, 198, 528 - 534
Outcomes of older patients aged 60 to 70 years undergoing reduced intensity transplant for acute myeloblastic leukemia: results of the NCRI acute myeloid leukemia 16 trial.
Journal article
Russell NH. et al, (2022), Haematologica, 107, 1518 - 1527
Historical controls and venous thromboembolism prophylaxis in acute lymphoblastic leukaemia: things can only get better?
Journal article
Hills RK., (2022), Br J Haematol, 197, e26 - e27
Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials.
Journal article
Early Breast Cancer Trialists' Collaborative Group (EBCTCG) None., (2022), Lancet Oncol, 23, 382 - 392
Gemtuzumab ozogamicin in (KMT2A)-rearranged adult acute myeloid leukaemia (AML) in the UK Medical Research Council AML15 and AML16 trials.
Journal article
Dillon R. et al, (2022), Br J Haematol, 196, e50 - e52
Therapy for isocitrate dehydrogenase 2 (IDH2)R172 -mutant acute myeloid leukaemia.
Journal article
Linch DC. et al, (2022), Br J Haematol, 196, 1348 - 1352
Treatment intensification with FLAG-Ida may improve disease control in younger patients with secondary acute myeloid leukaemia: long-term follow up of the MRC AML15 trial.
Journal article
Russell N. et al, (2022), Br J Haematol, 196, 1344 - 1347
High on-treatment platelet reactivity-an OPTIMAl solution, or a better solution?
Journal article
Hills RK., (2022), Br J Haematol, 196, 272 - 273
Randomized evaluation of quizartinib and low-dose ara-C vs low-dose ara-C in older acute myeloid leukemia patients.
Journal article
Dennis M. et al, (2021), Blood Adv, 5, 5621 - 5625
Genome-wide association study identifies susceptibility loci for acute myeloid leukemia.
Journal article
Lin W-Y. et al, (2021), Nat Commun, 12
Survivin' Acute Myeloid Leukaemia-A Personalised Target for inv(16) Patients.
Journal article
Greiner J. et al, (2021), Int J Mol Sci, 22
Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials.
Journal article
Early Breast Cancer Trialists’ Collaborative group (EBCTCG) None., (2021), Lancet Oncol, 22, 1139 - 1150
Diagnosing Diamond-Blackfan anaemia: 'vorsprung durch technik'.
Journal article
Hills RK., (2021), Br J Haematol
A randomised evaluation of low-dose cytosine arabinoside (ara-C) plus tosedostat versus low-dose ara-C in older patients with acute myeloid leukaemia: results of the LI-1 trial.
Journal article
Dennis M. et al, (2021), Br J Haematol
Additional impact of mutational genotype on prognostic determination in resistant and relapsed acute myeloid leukaemia.
Journal article
Linch DC. et al, (2021), Leuk Res
Characteristics and outcome of patients with acute myeloid leukaemia and t(8;16)(p11;p13): results from an International Collaborative Study.
Journal article
Kayser S. et al, (2021), Br J Haematol, 192, 832 - 842
Defining the Optimal Total Number of Chemotherapy Courses in Younger Patients With Acute Myeloid Leukemia: A Comparison of Three Versus Four Courses.
Journal article
Burnett AK. et al, (2020), J Clin Oncol